Key TakeawaysAbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its purchase of Cerevel Therapeutics.The biotech company reported in November that the schizophrenia drug, emraclidine, didn't reach primary endpoints in a Phase 2 trial.Abbvie explained that following the study, it began an evaluation of the impact of the results, "which resulted in a significant decrease in the estimated future cash flows for the product." AbbVie (ABBV) shares fel ...

MoneyShow — an industry pioneer in investor education since 1981 — is a global, financial media company, operating the world's leading investment and trading conferences. Each show brings together thousands of investors to attend workshops, presentations and seminars given by the nation's top financial experts. The company also offers exclusive seminars-at-sea, with the investment industry's leading partners. In addition, MoneyShow operates the award-winning, multimedia online community, Moneyshow.com and p ...

AbbVie Inc. (NYSE: ABBV ) looks like an apparent 'Strong Buy' not only because of the 17% upside potential derived by my DCF model. The business is fundamentally strong with a solid diversified business mix, which is protected by long-term patents forComing from an IT background, I have dived into the U.S. stock market seven years ago by managing portfolio of my family. Starting managing real money has been challenging for the first time, but long hours of mastering fundamental analysis of public companies ...

NORTH CHICAGO, Ill., Jan. 9, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Management will participate in a fireside chat at 10:15 a.m. Central time.A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.About AbbVieAbbVie's mission is to discover and deliver innovative medici ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering AbbVie (ABBV) , which belongs to the Zacks Large Cap Pharmaceuticals industry.This drugmaker has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 2.93%.For the last reported quarter, AbbVie came out with earnings of $3 per share versus ...

Get Treated with CoolSculpting® Elite and Enter for a Chance to Win $10,000* Starting Today, First-Time Users Can Claim $300 Off Their Treatment† IRVINE, Calif., Jan. 7, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its third annual CoolMonth featuring CoolSculpting® Elite. The celebration is an opportunity for consumers interested in body contouring to reach out to a CoolSculpting® Elite expert and discuss their body contouring treatment options. CoolSculpting® is the ...

In an SEC filing, AbbVie (ABBV) has disclosed that it is lowering its previously issued guidance for 2024 adjusted earnings per share (EPS) by 88 cents due to in-process research and development (IPR&D) expenses incurred for acquisitions and collaborations during the fourth quarter.The adjusted EPS guidance for full-year 2024 was lowered from $10.90-$10.94 to $10.02-$10.06 due to acquisition costs of $1.6 billion on a pre-tax basis. The Zacks Consensus Estimate for this metric is pegged at $10.96.Including ...

收购IPR&D和里程碑费用影响 - 2024年第四季度预计将产生16亿美元的收购IPR&D和里程碑费用，对GAAP和调整后非GAAP每股收益产生0.88美元的不利影响[5] - 2024年全年调整后每股收益指引范围为10.02至10.06美元，包括第四季度收购IPR&D和里程碑费用的影响[6] - 2024年第四季度调整后每股收益指引范围为2.06至2.10美元，包括第四季度收购IPR&D和里程碑费用的影响[6] 收购IPR&D和里程碑费用的不确定性 - 公司未预测收购IPR&D和里程碑费用，因未来交易的发生和时间存在不确定性[6]

股息投资策略 - 股息投资有两种基本策略：一种是选择股息快速增长的公司，但这些股票通常收益率较低；另一种是选择高股息收益率的股票，但这类股票通常存在股息支付能力的不确定性 [1] AbbVie公司分析 - AbbVie自2013年从Abbott Laboratories分拆以来，股息支付增长了310%，目前股息收益率为3.6% [3] - 公司2023年对Cerevel Therapeutics的87亿美元投资未达预期，但Cerevel开发的帕金森病治疗药物tavapadon在3期临床试验中达到主要终点，未来可能带来数十亿美元年收入 [4][5][6] - 公司主要药物Skyrizi在2024年前9个月销售额同比增长48%至79亿美元，另一款药物Rinvoq同期销售额增长52%至41亿美元 [6][7] - 截至2023年9月的12个月内，公司产生156亿美元自由现金流，仅用70%支付股息 [8] W.P. Carey公司分析 - W.P. Carey是一家房地产投资信托基金(REIT)，目前股息收益率为6.4% [9] - 公司2023年决定分拆办公楼资产组合并相应降低股息支付 [10] - 公司最大租户Extra Space Storage仅占年化基础租金的2.7%，具有较强的经济衰退抵御能力 [12] - 自2023年降低股息以来，公司已四次提高股息支付，预计调整后运营资金(FFO)将达到4.68美元，远高于当前3.52美元的年度股息支付 [13]

医疗行业投资机会 - 医疗行业在宏观经济好坏情况下都能保持增长 是投资者可以依赖的领域 [2] - 美国2023年医疗支出达4.9万亿美元 同比增长7.5% [5] - 美国2023年处方药支出达4500亿美元 同比增长11.4% [7] Medtronic公司分析 - 公司始于1950年代的心脏起搏器业务 目前心血管设备仍是主要业务 还包括慢性背痛植入设备等 [4] - 公司连续47年提高股息 目前股息收益率3.5% [5] - 2023年公司自由现金流55亿美元 仅需66%即可满足股息支付 [6] Bristol Myers Squibb公司分析 - 公司连续16年提高股息 目前股息收益率4.3% [7] - 抗凝血药Eliquis第三季度销售额30亿美元 占总收入25% 但2028年可能面临仿制药竞争 [8] - 公司增长产品组合占总销售额49% 第三季度同比增长18% [9] - 抗癌药Opdivo注射剂获FDA批准 第三季度输液版销售额23亿美元 [10] AbbVie公司分析 - 公司自2013年从Abbott分拆后 股息已增长超4倍 目前股息收益率3.7% [12] - 2024年前9个月Humira销售额同比下降34%至73亿美元 [13] - 2019年上市药物Skyrizi和Rinvoq抵消Humira损失 第三季度销售额分别同比增长51%和45% [14] - 预计2025年及以后公司可实现高个位数增长 [14]